Panel 3

Lin, Jizhen

2017-04


http://hdl.handle.net/10138/198025
https://doi.org/10.1177/0194599816685559

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
Panel 3: Genetics and Precision Medicine of Otitis Media

Jizhen Lin, MD¹, Hena Hafre´n, MD², Joseph Kerschner, MD³, Jian-Dong Li, MD, PhD⁴, Steve Brown, PhD⁵, Qing Y. Zheng, MD⁶, Diego Preciado, MD, PhD⁷, Yoshihisa Nakamura, MD, PhD⁸, Qiuhong Huang, MD, PhD⁹, and Yan Zhang, MD, PhD¹⁰

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Abstract

Objective. The objective is to perform a comprehensive review of the literature up to 2015 on the genetics and precision medicine relevant to otitis media.

Data Sources. PubMed database of the National Library of Medicine.

Review Methods. Two subpanels were formed comprising experts in the genetics and precision medicine of otitis media. Each of the panels reviewed the literature in their respective fields and wrote draft reviews. The reviews were shared with all panel members, and a merged draft was created. The entire panel met at the 18th International Symposium on Recent Advances in Otitis Media in June 2015 and discussed the review and refined the content. A final draft was made, circulated, and approved by the panel members.

Conclusion. Many genes relevant to otitis media have been identified in the last 4 years in advancing our knowledge regarding the predisposition of the middle ear mucosa to commensals and pathogens. Advances include mutant animal models and clinical studies. Many signaling pathways are involved in the predisposition of otitis media.

Implications for Practice. New knowledge on the genetic background relevant to otitis media forms a basis of novel potential interventions, including potential new ways to treat otitis media.

Keywords

otitis media, genetics, precision medicine

Received November 30, 2015; revised October 11, 2016; accepted December 1, 2016.

Genetics is critical in otitis media (OM) pathogenesis, an infectious disorder involving inflammation of the middle ear. Family and twin studies have proven that the heritability of OM is high. Multiple factors and many genes are involved in the predisposition of OM. The genetic risk factors include the transforming growth factor beta (TGFβ) signaling pathway, mucin genes, vascular endothelial growth factor, Toll-like receptors (TLRs), and ERK signaling pathways. These pathways overlap and affect innate/adaptive immunity and inflammatory responses of the middle ear mucosa or normal cellular functions (angiogenesis, hypoxia, lymphangiogenesis, mucociliary transport system, mucin production, and mucous cell metaplasia). Increased understanding of these genes and pathways has led to novel therapeutic strategies for OM. Precision medicine (PM)—the use of specific patient genotypic and phenotypic characteristics to inform individualized therapeutic decisions—has also emerged as a consideration for OM management. Tools in PM include molecular diagnostics by panomic analysis and systems biology to understand the specific causes underpinning a patient’s OM pathogenesis.

¹Department of Otolaryngology–Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA
²Departments of Otorhinolaryngology–Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
³Department of Otorhinolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
⁴Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA
⁵Medical Research Council Harwell Institute, Oxfordshire, UK
⁶Department of Otolaryngology–Head and Neck Surgery, Case Western University, Cleveland, Ohio, USA
⁷Sheikh Zayed Institute for Pediatric Surgical Innovation, Pediatric Otolaryngology, Children’s National Health System, Washington, DC, USA
⁸Department of Otolaryngology, Nagoya City University, Nagoya, Japan
⁹Department of Otolaryngology, Sun Yat-sen University, Guangzhou, China
¹⁰Department of Otolaryngology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

Corresponding Author:
Jizhen Lin, MD, Department of Otolaryngology–Head and Neck Surgery, University of Minnesota, 2001 6th Street SE, Minneapolis, MN, USA.
Email: linxx004@umn.edu
Method and Search Strategy

Published literature in PubMed was searched since the last symposium. Search terms included OM, recurrent acute OM, chronic OM, chronic OM effusion, acute OM, heritability, genetic, SNP, genes, genetic polymorphism, GWAS, linkage study, genetics, signaling pathways, mucins, transforming growth factor beta, Toll-like receptor, mucosal metaplasia, chinchilla genome, and animal model. The search included all published literature with available English abstracts. No further exclusion or selection criteria were employed.

Discussion

Recent Advances in the Genetics of OM

Chronic infectious diseases, including OM, have been linked to specific genetic profiles. For example, TLR2-deficient mice develop purulent OM because of abundant infiltration of neutrophils related to the absence of goblet cell metaplasia/hyperplasia in the middle ear mucosa. 1 The genetic background interacts with other host and environmental factors to affect the phenotype of OM. Several animal model studies, as well as human studies, have solidified the link between OM phenotypes and genetics. 2

The branch of PM that addresses OM is referred to as “precision OM,” based on OM properties and genetic backgrounds, such as chronic OM, secretory OM, serous OM, mucous OM, and silent OM. A genetic predisposition or susceptibility to OM is a genetic characteristic feature that influences the possible phenotypic development. Genetic testing and analysis can identify individuals who are genetically predisposed or susceptible to certain OM phenotypes.

Precision Medicine in OM

Understanding of disease susceptibility factors (intrinsic and extrinsic), the characteristics of the pathogens, and how these potentially affect a patient provides a basis for precision medical care for OM. 3 Recent literature has highlighted the importance of distinguishing patterns of illness in acute OM to enable appropriate precision and individualized care. 4 Currently, these concepts apply primarily to clinical presentations, such as bilateral acute disease, to inform the use of antibiotics or surgical intervention. 5 However, the ability to use patient-specific genetic information to similarly influence treatment decisions has been much studied and published since the last symposium.

In OM, PM offers the potential to tailor a medical treatment to a subgroup of individuals who have similar genetic backgrounds, susceptibilities to pathogens, and responses to external stimuli. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and potential complications to those who will not.

Genetic Aspect of Inflammation

Inflammation is a hallmark of OM. Appropriate inflammation is essential for eradicating pathogens. However, excessive inflammation is clearly detrimental to the host. Uncontrolled inflammation in the middle ear significantly contributes to the development and progression of OM. Thus, inflammation must be tightly regulated. However, little is known about how inflammation is regulated in the pathogenesis of OM.

A number of studies were carried out to investigate the role of proinflammatory mediators in OM, with in vitro and in vivo approaches. Zhang et al 6 found that blockade of macrophage migration inhibitory factor suppresses inflammation and improves the hearing level in an acute OM model. From a whole genome gene array analysis, Suzukawa et al 7 identified that heparin binding–epidermal growth factor is a key mediator of inflammation-induced mucosal proliferation in a mouse model of OM. Kurabi et al 8 found that mice lacking ASC, the inflammasome adaptor protein, exhibited impairment of IL-1β maturation, reduction in neutrophil recruitment, and bacteria clearance of nontypable Haemophilus influenzae (NTHi) in middle ear. Preciado et al 9 found that NTHi challenge in the mouse middle ear led to chronic epithelial mucosal metaplasia and that Cxcl2 was a key proinflammatory mediator.

Investigating the negative regulators of inflammation over the past years also brought novel insights into the tight regulation of inflammatory responses. Woo et al 10 found that IL-10/HMOX1 signaling played a critical role in protecting the cochlea from inflammation-mediated tissue damage through inhibition of MCP-1/CCL2 regulation. Wang et al 11 found that deubiquitinase cylindromatosis (CYLD) suppressed NTHi-induced expression of key proinflammatory chemokine IL-8 via MAP kinase phosphatase 1 (MKP-1)-dependent inhibition of ERK. In addition, Komatsu et al 12 identified phosphodiesterase 4B (PDE4B) as a key negative regulator for CYLD, and inhibition of PDE4B markedly suppressed bacteria-induced inflammation via upregulating CYLD expression by siRNA technology and Cyld-deficient mice. Taken together, all of these studies may lead to the development of new anti-inflammatory therapeutics by targeting key regulators of inflammation in OM.

Genes Relevant to Human OM

Genetic studies are one way to research the pathophysiology behind OM and eventually find new strategies for the therapy and prevention of OM. There are several strategies to conduct human genetic studies.

Heritability Studies

Heritability is the variance of phenotypic variation due to genotype and has been estimated on twin studies for OM. Hafren et al estimated heritability from an OM-prone cohort of 590 families, consisting of 2436 subjects. The heritability estimates were 38.5% for recurrent acute OM, 22.1% for OM with effusion, and 47.8% for all OM. 13,14 These results were somewhat lower than heritability estimates from twin studies.

Linkage Studies

The purpose of linkage studies is to find genomic loci associated to a phenotype. One or several families are genotyped, and with information about the affected status of the
subject and genotype, the loci are calculated. Chen et al did a follow-up linkage study, fine-mapping chromosome 19 on their cohort of 139 families consisting of 607 study subjects. They replicated their previous finding of linkage to loci 19q (LOD$_{best} = 3.75$)\textsuperscript{15} Rye et al did a linkage study on a cohort of 468 subjects from 101 families. They found significant evidence of linkage to 10q26.3 (Z$_{tr} = 2.69$, P = .0036) and borderline linkage to 10q22.3 (Z$_{tr} = 1.67$, P = .05). They further fine mapped the region in a cohort of 256 affected cases and 575 controls with imputation data from a previous genome-wide association study (GWAS) that revealed 4 candidate genes: TCERG1L, PP2R2D, DOCK1, and ADAM12. Expression analysis and in silico analysis concluded that $PPP2R2D$, part of the TGFβ pathway, is the most likely candidate gene underlying the linkage result.\textsuperscript{16}

**Candidate Gene Association Studies.** In candidate gene studies, the frequencies of a genetic marker is compared between affected study subjects and control subjects. The control subjects can be unrelated healthy controls (case-control study) or healthy siblings or other family members (family study). Sale et al conducted a candidate gene study on 15 genes with separate polymorphisms in 142 families with 618 subjects. Nominal genetic association was found for $MUC5AC$ (rs2735733, $P = .002$, odds ratio [OR] = 0.646; rs7396030, $P = .049$, OR = 1.565; rs2075859, $P = .041$, OR = 0.744). Three other single-nucleotide polymorphisms (SNPs) at 3 separate genes showed a trend toward association: $SCN1B$ (rs810008, $P = .013$), $SFTPD$ (rs10151246, $P = .039$), and $TLR4$ (rs2770146, $P = .038$).\textsuperscript{17} Rye at al studied the candidate gene $SLC11A1$ in 660 affected children from 531 families in a case/pseudo-control study. The best SNP association was in the genetic model at the rs2776631 allele (C) with $OR = 3.6$, 95% confidence interval: 1.4-8.9).\textsuperscript{22} Primary ciliary dyskinesia is a genetic disease inherited in an autosomal recessive manner. The prevalence of primary ciliary dyskinesia is estimated to be 1 in 20,000 live births. Congenital abnormality of the primary cilia results in situs inversus in 50% of patients. Decreased function of motile cilia causes chronic rhinosinusitis, OM with effusion, bronchiectasis, and infertility.\textsuperscript{23} Hafren et al did a candidate gene study with 53 SNPs on 624 study subjects with recurrent acute OM and/or chronic OM with effusion and 778 control subjects. The positive result for $TLR4$ (rs5030717, $OR = 1.33$, $P = .003$) was further investigated by a tagging SNP analysis, and 2 additional SNPs were identified (rs1329060 and rs1329057). There was an increased association among patients with a more severe phenotype; those with OM starting before the age of 6 months (OR = 2.42, $P = .0005$, for rs1329060) and those with repeated insertions of tympanostomy tubes (OR = 1.65, $P = .0004$ for rs1329060). The result was replicated in a Finnish OM cohort of 205 children (rs1329060, $OR = 1.32$, $P = .002$; rs1329057, $OR = 1.30$, $P = .003$; rs5030717, $OR = 1.34$, $P = .002$). In 3 other cohorts (2 in the United States and 1 in United Kingdom), the 3 SNPs failed to show association with the risk for OM.\textsuperscript{25}

A $TLR4$ variant (Asp299Gly, rs4986790) is related to the colonization of *Moraxella catarrhalis* in the upper respiratory tract of children (43%) in comparison with the $TLR4$ wild type (9%) (RR = 4.91, $P = .0001$).\textsuperscript{24,25} The IL-10 rs1800896TC SNP and the IL-1α rs6746923A and AG SNPs were significantly more and less common, respectively, among children without a history of tympanic membrane perforation than among those who suffered from this complication.\textsuperscript{26}

**Genome-wide Association Studies.** Genome-wide association studies (GWASs) require no previous assumption on underlying genetic loci. They are used in the research of common, complex diseases. Hundreds of thousands to millions of SNPs are analyzed in cases and controls to find SNPs associated to the trait. Two GWASs have been published on OM.

The first was published by Australian colleagues Rye et al in 2012. They used the Illumina 660W-Quad to study 416 affected cases and 1075 controls. No marker showed genome-wide significance ($P < 10^{-8}$), but there was a trend toward association in the genes $CAPN14$ and $GALNT14$ on chromosome 2p23.1 and $BPIFA3$ and $BPIFA1$ on chromosome 20q11.21. The top results did not replicate in an independent cohort of 793 affected study subjects from 645 families, nor did they replicate in a North American cohort of 596 subjects and 370 affected.\textsuperscript{27}

The second GWAS study on OM was conducted on a North American cohort of 602 study subjects from 143 families, with 373 affected subjects. Allen et al used the Illumina Human CNV370-Duo. No SNP reached genome-wide significance, but they conducted a replication study on 53 SNPs in an independent cohort of 1584 study subjects.
from 441 families. In an intergenic region on chromosome 2, the SNP rs10497394 replicated, thus giving a significant association to OM ($P_{META\text{-}ANALYSIS} = 1.52 \times 10^{-6}$). Three other SNPs on chromosomes 15 and 5 showed a trend toward association. Allen et al.28 noted that diagnostic approaches such as human linkage studies and GWASs may provide new insights to OM research for the development of novel therapeutic strategies.

Sequencing. Sequencing is becoming more affordable these days and is mainly used to find rare variants in rare diseases. In recent years, there has also been an increasing number of studies on complex diseases. In 2015 Santos-Cortez et al. published the first sequencing study on OM. They did exome sequencing on 2 second cousins in a Filipino isolate population where the prevalence of OM is almost 50%. They found a variant of A2ML1 ($\alpha$-macroglobulin-like 1) as a new risk variant for OM. The result was replicated in 51 other subjects in the same isolate (LOD, 7.5). The variant is due to a duplication in the gene (pSer829Trpfs*9). A2ML1 is expressed in murine middle ear and is a rare, high genetic–risk variant for OM.

Genes Involved in Hearing Loss and OM in Animal Models

The mouse model is a useful tool to study and identify the genes relevant to OM. The advance in genetic studies through mutant mice is summarized in Table 1.30-61

Genes Whose Deficiency Results in OM

There are genes that are essential for the maintenance of the middle ear epithelial cell integrity and health. The deficiency of the following genes results in OM. (1) Tgif1—it functions through several routes as a negative regulator of the TGFB signaling pathway. Tgif1 mutant mice have significantly raised auditory thresholds due to a conductive deafness arising from OM.37 (2) Phex—a mutation in the Phex gene is linked to predisposition to OM in mice. The mutation in the Phex gene primarily upregulates the expression level of the FGF23 gene in the middle ears.39

There is a report where FGF23 mutant mice showed mixed hearing loss and middle ear malformation.62 (3) Oxgr1—the Oxgr1 gene encodes oxoglutarate receptor 1. The ligand for Oxgr1 was reported to be involved in regulation of vascular endothelial growth factor, an important inducer of angiogenesis and vascular permeability. Oxgr1 deficiency demonstrated the presence of inflammatory cells, changes in the mucosal epithelium, and middle ear fluid in mice.38 (4) Mcph1—the Mchph1-deficient mice had mild to moderate hearing impairment (around 70% penetrance). Other defects of Mcph1-deficient mice included small skull sizes, increased micronuclei in red blood cells, increased B cells, and ocular abnormalities.36 (5) Dfl—the Dfl gene is cytogenetic risk factor for schizophrenia and can cause hearing difficulties as well as a variety of other medical problems.63 (6) Lmna—mutant Lmna mice exhibited profound early-onset hearing deficits and abnormal positioning of the eustachian tube accompanied by OM.40 (7) Spag6—mammalian sperm-associated antigen 6 (Spag6) is required for normal flagella and cilia motility. The deficiency of this gene in humans causes OM due to accumulation of fluid and mucociliary abnormality.32

Genes Associated with Virulence in OM

(1) Hfq—in the chinchilla model of OM, the hfg mutant of 86-028NP exhibited impaired competitive fitness when compared with its wild-type progenitor but exhibited no apparent defect in virulence to elicit OM.64 (2) HemR—this gene is involved in the uptake of iron and iron-containing moieties, essential for Haemopilus. Variability of the HemR polymorphism may result in a reduced ability to acquire iron, rendering NTHi unable to survive in the middle ear.65 (3) Fur—this gene is also essential for Haemopilus to grow in the middle ear.66 (4) VapBC-1 VapXD ToxAVapA—deletions in vapBC-1, vapXD, and ToxAVapA significantly decreased the survival of NTHi in the chinchilla model of OM.67,68

Signaling Pathways and Inflammatory Factors Involved in OM

(1) Asc—mice lacking the Asc gene showed a reduction in leukocyte recruitment and infiltration to the cavity, and their macrophages exhibited reduced phagocytosis of NTHi.5 (2) Pai-1—plasminogen activator inhibitor (PAI-1) regulates inflammatory cell migration. PAI-1 knockout mice showed significant pathologic changes of tympanosclerosis.30 (3) C5a—mice deficient in the C5a gene showed the reduced levels of IL-6, mKC, and MCP-1, in association with reduced inflammatory cell recruitment, mucosal inflammation, and bacterial clearance.69 (4) IL-17a—the function of interleukin 17A (IL-17A), a neutrophil-inducing factor. Mice lacking the IL-17A gene were associated with abnormal recruitment and apoptosis of neutrophils.70

Mucin OM

Cxc12 is identified as the most significant increased inflammatory mediator during the early acute phase of infection.9 Math1, a critical transcription factor, with proinflammatory cytokine tumor necrosis factor alpha (TNFα) and retinoid acid, promoted differentiation of normal mouse middle ear epithelium into mucus-producing cells via upregulation of mucins and trefoil factors. This results in pathologic mucous cell metaplasia and increased susceptibility of chronic OM.34 GalNAC residue essential for binding of bacteria to respiratory epithelium is localized in mucus-producing epithelium and submucosal glands of normal rat eustachian tube.71 Combination of certain NTHi and Streptococcus pneumoniae strains, but not all, worked synergistically to upregulate the gel-forming mucin transcripts. Mucins play a protective role in the epithelium but with their dysregulation can lead to mucus stasis.72 Acrolein, a hazardous air pollutant in tobacco smoke, promoted inflammatory responses, mucin gene expression, and cell death in human middle ear epithelium culture.73 Other air-suspended urban particles, both artificial and naturally occurring, induced COX-2 and MUC5AC expression in...
<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant and Strain Background</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAI-1</td>
<td>Type 1 plasminogen activator inhibitor (PAI-1) knockout PAI-1 KO mice (B6.129S2-Serpine1tm1Mlg)</td>
<td>Low levels of inflammation against NTHi at the early stage of OM and fail to terminate inflammation.30</td>
</tr>
<tr>
<td>JNK1</td>
<td>JNK1 knockout, C57BL/6</td>
<td>Exhibit enhanced mucosal thickening, with delayed recovery, enhanced neutrophil recruitment early in OM, and delayed bacterial clearance.31</td>
</tr>
<tr>
<td>JNK2</td>
<td>JNK2 knockout C57BL/6</td>
<td>Delayed mucosal hyperplasia, delayed recruitment of neutrophils, and failure of bacterial clearance.31</td>
</tr>
<tr>
<td>SPAG6</td>
<td>Sperm-associated antigen 6 (Spag6)-deficient mice</td>
<td>Associated with disordered cilia orientation, leading to uncoordinated cilia beating.32</td>
</tr>
<tr>
<td>HB-EGF</td>
<td>C57BL/6:CB F1 hybrid mice</td>
<td>Inducing mucosal epithelial hyperplasia in vitro.7</td>
</tr>
<tr>
<td>TBX21</td>
<td>Tbx21-deficient mice (C.129S-Tbx21tm1Glm/J)</td>
<td>TBX21 regulating innate immune responses, via TLR2 during pneumococcal infections.33</td>
</tr>
<tr>
<td>Math1</td>
<td>Mouse middle ear epithelial cells</td>
<td>Plays a critical role in the pathogenesis of OM by induction of mucous cell differentiation, in the presence of TNFα and retinoid acid.34</td>
</tr>
<tr>
<td>Pax9</td>
<td>Pax9 mutant homozygosity for Slc25a21tm1a(KOMP)Wtsi</td>
<td>OM and hearing impairment in mice may be due to disrupted Pax9 expression.35</td>
</tr>
<tr>
<td>Mcph1</td>
<td>A knockout-first allele in which a promoter-less cassette including LacZ and neo genes were inserted in intron 3-4 of the Mcph1 gene, Mcph1-deficient (Mcph1tm1a(EUCOMM)Wtsi)</td>
<td>Underlying genetic predisposition to OM.36</td>
</tr>
<tr>
<td>TGFβ</td>
<td>TGFβ knockout, Tgf1 homozygous mutant mice on a C57BL/6J background</td>
<td>A role of TGFβ signaling and its impact on responses to hypoxia in the inflamed middle ear.37</td>
</tr>
<tr>
<td>Oxgr1</td>
<td>Mutant (Oxgr1&lt;sup&gt;−/−&lt;/sup&gt;)</td>
<td>A trend of increase in Muc5B and Muc19 expression in the middle ear.38</td>
</tr>
<tr>
<td>Phex</td>
<td>A spontaneous intragenic deletion involving at least 30 kb containing Phex exons 13 and 14, BALB/c-Phex&lt;sup&gt;30kb-Duk/Y&lt;/sup&gt;</td>
<td>Affecting the FGF23 mediated pathways in the middle ears, predisposition to OM.39</td>
</tr>
<tr>
<td>Lmna</td>
<td>Mutant Lmna mice heterozygous (Lmna&lt;sup&gt;Dho/+&lt;/sup&gt;)</td>
<td>A model of human OM and laminopathy.40</td>
</tr>
<tr>
<td>Chd7</td>
<td>Spontaneous deletion of Chd7 exons 2-3I2</td>
<td>OM with effusion.41</td>
</tr>
<tr>
<td>Tc1</td>
<td>Tc1 mouse model of Down syndrome, C57BL/6J129S8 background</td>
<td>A limited region of human chromosome 21 involved in OM.42</td>
</tr>
<tr>
<td>HIF</td>
<td>Junbo and Jeff mouse mutant models</td>
<td>The role of hypoxia and HIF-mediated pathways.43</td>
</tr>
<tr>
<td>Isl1</td>
<td>A nonconservative tyrosine to cysteine (Y71C) missense mutation in the Islet1 gene, Isl1&lt;sup&gt;Y71C&lt;/sup&gt; Drsh. C3HeB/FeJ background</td>
<td>Predisposition carriers to OM.44</td>
</tr>
<tr>
<td>Sh3pxd2b</td>
<td>Sh3pxd2b&lt;sup&gt;nee&lt;/sup&gt; heterozygous mice</td>
<td>All mice that had the Sh3pxd2b&lt;sup&gt;nee&lt;/sup&gt; mutation went on to develop craniofacial dysmorphologies and subsequently OM, by as early as 11 days of age.45</td>
</tr>
<tr>
<td>Factor B</td>
<td>C57BL/6 mice</td>
<td>Factor B deficiency decreases C3 activation during acute pneumococcal OM. Complement C3 activation and opsonophagocytosis of S. pneumoniae were greatly attenuated in factor B- and factor B/C2-deficient mice.46</td>
</tr>
<tr>
<td>TNFA</td>
<td>TNFA deletion</td>
<td>The TNF and TNF receptor superfamilies mediate both inflammation and apoptosis during OM. TNFA is also required for appropriate regulation of caspase genes.47</td>
</tr>
<tr>
<td>TLR9</td>
<td>Toll-like receptor 9&lt;sup&gt;−/−&lt;/sup&gt; mice on a C57BL/6 background</td>
<td>DNA sensing via TLR9 plays a role in OM pathogenesis and recovery.48</td>
</tr>
</tbody>
</table>

(continued)
human middle ear epithelium culture. Injection of urban particle solution into rat middle ear induced mucosal changes and dysregulation of genes associated with inflammatory response and mucin production. The impact of these environmental exposures on mucin regulation and mucosal changes conferred the development of OM.

Immune Tolerance of Middle Ear Mucosa

Clinically, the middle ear is considered an immune-privileged area. Homografts of the tympanic membrand usually survive for a long time without administration of any immunosuppressive drugs after surgery. For this reason, the middle ear is tolerant to the invading upper respiratory commensals that reside and thrive, frequently causing OM. Consistent with this, immune- and inflammatory-related cytokines, such as TNF-α and interferon gamma, are induced, which regulate the immunity of the middle ear mucosa against infectious agents. Programmed death ligand 1 (PD-L1), an inducible protein in the middle ear epithelial cells, is induced, which inhibits
middle ear immunity when PD-L1 binds to its receptor, programed death 1 (PD-1), on the surface of mucosal lymphocytes. This way, the PD pathway is formed in the middle ear mucosa to suppress the immunity of the middle ear, making a regional immunotolerance at this specific tissue while the entire immune system is normal.

PD-L1 negatively regulates the activity of effector T lymphocytes, including intraepithelial lymphocytes, in the mucosa, reducing the production of IL-2, which is a major cytokine to expand T cells. T cells participate in the innate and adaptive immunity. Due to the negative effects of PD-L1 on the T-cell activity, the innate and adaptive immune systems are both suppressed, and invading microorganisms survive and thrive in the middle ear. This is a unique phenotype of OM characterized by the activation of the PD pathway. In this particular phenotype of OM, the PD pathway may serve as a novel target for the treatment of OM.

**New Intervention for OM**

Nonconventional approaches to treatment were examined in an OM animal model. The noninvasive transcutaneous immunization to induce protective immune responses against NTHi-induced OM was conducted in the chinchilla model. The vaccine formula, utilizing a new chimeric immunogen, targeted 2 important bacterial outer membrane proteins and effectively removed mucosal surface bacteria and mucosal biofilm in the middle ear. The increase of activated T cells and the release of host defense peptide contributed to a rapid disease resolution. Antimicrobial activity of photodynamic therapy with porphyrin sodium (PhotoFrin) was assessed against clinical isolates of Mcat. The treatment demonstrated significant reduction in planktonic bacteria and viable bacteria in the biofilm structure.

Various drug delivery methods were attempted to improved efficacy of OM treatment. OTO-201, a sustained-release formula of ciprofloxacin administered via intratympanic injection, was proved to be more effective and convenient in OM treatment. Levofloxacin thermosensitive gel allowed on-site delivery and prolonged the release of antibiotics in the middle ear space. This characteristic provides effective treatment of suppurative OM without recurrence.

In summary, there have been more animal models available for genetic studies regarding OM in recent years and more genes in animal models and human genetic linkage studies relevant to the pathogenesis of OM. In general, these studies are evolving, and the relationship between these genes and human OM remains to be clarified in the years to come.

**Author Contributions**

Jizhen Lin, overall writing; Lena Hafrén, writing in paragraphs regarding human genetics of otitis media; Joseph Kerschner, writing in paragraphs regarding precision medicine of otitis media, mucins, genetics, intervention etc; Jian-Dong Li, writing in paragraphs regarding inflammation and genetics; Steve Brown, writing in paragraphs and tables regarding the genes involved in otitis media; Qing Y. Zheng, writing in paragraphs and tables regarding the genes involved in otitis media; Diego Preciado, contributing to mucins in human otitis media; Yoshihisa Nakamura, contributing to paragraphs regarding gene polymorphisms and susceptibility; Qiuhong Huang, contributing to the molecular genetics of otitis media and related discussion and writing; Yan Zhang, contributing to the molecular genetics of otitis media and related discussion and writing.

**Disclosures**

**Competing interests:** Joseph Kerschner, AventaMed—scientific advisor; Steve Brown, Audition Therapeutics Ltd—co–chief scientific officer, shareholder; Pulmagen Therapeutics Ltd—shareholder; CNR Monterotondo, Rome—consultant.

**Sponsorships:** None.

**Funding source:** None.

**References**


